Latest news with #Graves'
USA Today
a day ago
- Politics
- USA Today
Indiana school banned a mom for trying to protect her child. She's right to sue.
An Indiana mother's lawsuit against her children's school district raises important questions about parents' First and 14th Amendment rights. It's back-to-school season, and parents and kids around the country are prepping for the inevitable transition from summer fun to the fall grind. For one Indiana mom, the stakes are higher than normal. Nicole Graves has sued her school district, Whitley County Consolidated Schools in Columbia City, Indiana, in federal court with help from the Arizona-based Goldwater Institute. She alleges that her First and 14th Amendment rights were violated in a series of interactions with school administrators. All four of Graves' children still attend district schools, and she's rightly concerned – given how she's been treated – about potential retaliation from the administration. Here's what happened: According to the Goldwater Institute, in April 2024, Graves' seventh-grade daughter 'filmed her school bus driver walking up and down the aisle, smacking his belt against his hand with his pants falling and his underwear visible.' After that incident on her daughter's school bus, Graves set up a meeting with the school principal. She recorded the meeting because she wanted an accurate record of what transpired. When Graves wasn't satisfied with what the principal said, she posted the recording on social media. That angered school administrators, who contacted her via letter and told her she broke school policy by recording the meeting without permission. Even though Graves had been unaware of the policy, she was banned from school grounds and restricted in her communication with staff, unless she got written permission from the superintendent's office. Trump is right about homeless camps: Make them 'move out, IMMEDIATELY' | Opinion 1st Amendment protections go beyond speech alone, lawsuit says While that absurd punishment has expired, the lawsuit seeks to overturn the ban on recording, which remains in place. 'This is not fun for me,' Graves told the Indianapolis Star. 'This is not something I ever thought I would have to fight for. But I am more than happy to stand up and fight and talk to who I need to talk to to get things to change because I think it's important for all the families in this school district.' The complaint argues that the school's recording policy and the no-trespass and communication orders violate the First Amendment, 'which protects the right to record government officials in the performance of their duties.' Adam Shelton, the Goldwater staff attorney working with Graves, says these kinds of recordings fall squarely under the First Amendment. 'The First Amendment protects more than just speech, it also protects conduct that is inherently expressive and conduct that cannot be divorced from the speech creation process, like recording,' Shelton observed on X. 'This is especially true in situations involving parents and school officials.' Opinion: Sydney Sweeney's jeans ad triggers liberals. She looks good. They don't. Parental rights around the country are at stake While Democrats and teachers unions may think they know what's best for children, that's simply false. Parents do. This lawsuit also alleges that the school district violated Graves' constitutional right to direct her children's education. 'The orders also violate the Fourteenth Amendment's due process clause, which protects the fundamental rights of parents to control and direct the education and upbringing of their children,' the complaint states. 'This right is the oldest right that the Supreme Court has recognized as one of the 'liberties' protected by the due process clause.' Parents, not progressives, know their kids best. They should control education. | Opinion Graves' case reminded me of one I've written about before, regarding another Midwest mom who was shunned by her child's school district. Sandra Hernden of Michigan sued her school district in 2022 for violating her constitutional rights. She had complained to the school board about its COVID-19 policies in 2020, and board members responded by contacting her employer and then reporting her to the Biden administration's U.S. Department of Justice (remember how the DOJ went after parents as 'domestic terrorists'?). Hernden's case is ongoing. Steve Delie, an attorney with the Mackinac Center Legal Foundation that is representing Hernden, made oral arguments in June before the 6th U.S. Circuit Court of Appeals. 'Even if we assume there was no monetarily compensable injury, you're still talking about government officials taking advantage of their elected positions of power to silence opposition,' Delie told the court. 'That can't be the way society functions.' No, it can't. Kudos to these moms for their bravery and for standing up for parental rights everywhere. Ingrid Jacques is a columnist at USA TODAY. Contact her at ijacques@ or on X: @Ingrid_Jacques
Los Angeles Times
12-08-2025
- Health
- Los Angeles Times
Why Do We Get Goiters? Causes Go Beyond Iodine Deficiency
You see the patient. They have a goiter—an enlarged thyroid. But they live in an iodine-rich country. Eat a good diet. Their labs are normal. So why the swelling? For years, the answer we gave was simple. Too simple. Iodine [1] [2] [3]. Or a lack of it. The thyroid needs iodine to make its hormones. No iodine, the gland gets desperate. It grows bigger, hypertrophies, to try and soak up every last molecule from the blood. A neat story. Except it wasn't the whole truth. We started seeing holes in the theory. Goiters in places with plenty of iodine. People in deficient areas with no goiter at all. The story started to fall apart. Then the U-shaped curve data hit [8]. Too little iodine? Bad. But too much iodine? Also bad. This complicated things. Suddenly, our big public health fix—iodized salt—could actually be part of the problem for some. The thyroid wants what it wants. No more, no less. The mess extends to the gland itself. Goiters aren't all the same. Some are diffuse, a smooth swelling. Others are nodular. Lumpy. For a long time, we figured nodules were just the end stage of that long, desperate growth from iodine deficiency [10]. But that never felt quite right either. By 2001, we were already pointing out that the iodine story just didn't explain the facts on the ground [5]. Something else was at play. That 'something else' turned out to be a mix of things. Genetics, for one. We always suspected it; goiters run in families. But a 2011 genome-wide study gave us the proof [9]. It didn't just hint at a link. It found actual genetic addresses—four of them—tied directly to thyroid size and goiter risk. It's in the code. Some people are just built to have a bigger thyroid. Nothing to do with their diet. Then there's the hormonal engine. Thyroid-Stimulating Hormone, or TSH. It's the signal from the pituitary gland that tells the thyroid to work. When the gland is sluggish for any reason, the pituitary starts yelling. It cranks up TSH. And that constant hormonal shouting is a powerful growth signal [2] [3] [6]. It makes the thyroid swell. It's a key pathway. A final common denominator for a lot of goiters. And you can never, ever talk thyroid without talking about autoimmunity. This is the body attacking itself. In Hashimoto's, the immune system slowly chews up the gland, and the resulting inflammation and repair attempts make it swell. In Graves' disease, the immune system makes an antibody that acts like TSH on steroids, flooring the accelerator and making the whole gland grow [4]. These are huge causes of goiter. And they have nothing to do with iodine. It's a completely different mechanism of disease. So, the simple model is gone. We're left with a more complex, messier, but more accurate picture. A goiter isn't a disease. It's a sign. A physical clue that points to a whole menu of possible problems. We still check nutrition. Iodine is still critical. So are other things like selenium and iron [2] [3]. We don't worry so much about broccoli or cabbage—the so-called goitrogens—unless there's a real iodine deficiency to begin with. We're even questioning old villains like smoking; one big study found no real link in an iodine-rich population [7]. Now, we're even linking nodular goiters to things like metabolic syndrome, tying the thyroid into the body's overall systemic health [6]. What does this change? It changes how we work. We have to be better detectives. A goiter diagnosis is just the start. Is TSH driving this? Is it autoimmune? Is there a family history? Are the nodules suspicious [4]? The management has to fit the cause. For a small, quiet goiter, the right answer is often just to watch it. If it's iodine, we supplement [1] [2]. Sometimes we use thyroid hormone to suppress that TSH shouting. And for the big ones, the ones causing symptoms or cosmetic issues, surgery is still the best tool in the box [4]. The neat and tidy story of goiter is history. It's messy now. It's genetics. It's immunity. It's hormones. The real shift isn't a new pill. It's a change in thinking. It's realizing the enlarged thyroid isn't the problem itself. It's a symptom of a deeper story we have to figure out, one patient at a time. [1] Hughes, K., & Eastman, C. (2012). Goitre - causes, investigation and management. Australian family physician, 41(8), 572–576. [2] Knobel M. (2016). Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters. Journal of endocrinological investigation, 39(4), 357–373. [3] Medeiros-Neto, G., Camargo, R. Y., & Tomimori, E. K. (2012). Approach to and treatment of goiters. The Medical clinics of North America, 96(2), 351–368. [4] Bible, K. C., Kebebew, E., Brierley, J., Brito, J. P., Cabanillas, M. E., Clark, T. J., Jr, Di Cristofano, A., Foote, R., Giordano, T., Kasperbauer, J., Newbold, K., Nikiforov, Y. E., Randolph, G., Rosenthal, M. S., Sawka, A. M., Shah, M., Shaha, A., Smallridge, R., & Wong-Clark, C. K. (2021). 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, 31(3), 337–386. [5] Derwahl, M., & Studer, H. (2001). Nodular goiter and goiter nodules: Where iodine deficiency falls short of explaining the facts. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 109(5), 250–260. [6] Yildirim Simsir, I., Cetinkalp, S., & Kabalak, T. (2020). Review of Factors Contributing to Nodular Goiter and Thyroid Carcinoma. Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 29(1), 1–5. [7] Karatoprak, C., Kartal, I., Kayatas, K., Ozdemir, A., Yolbas, S., Meric, K., & Demirtunc, R. (2012). Does smoking affect thyroid gland enlargement and nodule formation in iodine-sufficient regions?. Annales d'endocrinologie, 73(6), 542–545. [8] Yu, X., Fan, C., Shan, Z., Teng, X., Guan, H., Li, Y., Teng, D., Jin, Y., Chong, W., Yang, F., Dai, H., Yu, Y., Li, J., Chen, Y., Zhao, D., Shi, X., Hu, F., Mao, J., Gu, X., Yang, R., … Teng, W. (2008). A five-year follow-up study of goiter and thyroid nodules in three regions with different iodine intakes in China. Journal of endocrinological investigation, 31(3), 243–250. [9] Teumer, A., Rawal, R., Homuth, G., Ernst, F., Heier, M., Evert, M., Dombrowski, F., Völker, U., Nauck, M., Radke, D., Ittermann, T., Biffar, R., Döring, A., Gieger, C., Klopp, N., Wichmann, H. E., Wallaschofski, H., Meisinger, C., & Völzke, H. (2011). Genome-wide association study identifies four genetic loci associated with thyroid volume and goiter risk. American journal of human genetics, 88(5), 664–673. [10] Teumer, A., Rawal, R., Homuth, G., Ernst, F., Heier, M., Evert, M., Dombrowski, F., Völker, U., Nauck, M., Radke, D., Ittermann, T., Biffar, R., Döring, A., Gieger, C., Klopp, N., Wichmann, H. E., Wallaschofski, H., Meisinger, C., & Völzke, H. (2011). Genome-wide association study identifies four genetic loci associated with thyroid volume and goiter risk. American journal of human genetics, 88(5), 664–673.
Yahoo
11-07-2025
- Business
- Yahoo
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428 International: 1 404-975-4839 Access Code: 899803 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call. The webcast will be archived on the Investor Relations section of About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@ (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@ (858) 345-6075
Business Upturn
30-06-2025
- Business
- Business Upturn
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves' hyperthyroidism and orbitopathy also to be featured SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced eight abstracts from its novel clinical development programs, including oral presentations featuring its lead investigational drug candidate, PALSONIFY™ (paltusotine)* and investigational candidate atumelnant, will be presented at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California. 'ENDO 2025 will be an incredibly meaningful moment for Crinetics in our mission to be the premier endocrine-focused global pharmaceutical company,' said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. 'For our lead investigational candidate PALSONIFY for acromegaly, we are excited to present long-term data that continue to support the durable, consistent response profile it has shown in earlier pivotal trials. Additionally, compelling Phase 2 trial results from atumelnant in CAH and new data from one of our early-stage development programs demonstrate that the Crinetics pipeline can address significant unmet needs.' Four abstracts will report results from the PALSONIFY development program, including an oral presentation featuring open-label extension data from the registrational Phase 3 PATHFNDR trials. This presentation will highlight long-term efficacy, safety, and symptom control in people with acromegaly who switched from injectable somatostatin receptor ligands (SRLs) to once-daily oral PALSONIFY. In addition, Crinetics will present three poster presentations: one evaluating symptom stability in acromegaly, one analyzing patient-reported outcomes from both PATHFNDR-1 and PATHFNDR-2 and another on PATHFNDR-2 open-label extension data. Together, these abstracts show PALSONIFY continues to be well tolerated, while providing consistent biochemical and symptomatic disease control. Crinetics will also present three abstracts from its atumelnant clinical development program, including an oral presentation of Phase 2 trial results in congenital adrenal hyperplasia (CAH). Additional presentations focus on reduction of adrenal volume and rapid and sustained reductions in potent 11-oxygenated androgens, a novel biomarker, in Phase 2 trial participants. Beyond its two lead programs, Crinetics will present new data from its early-stage pipeline, including data from CRN12755 for Graves' hyperthyroidism and orbitopathy. Additional presentation details are shown below. All times are PT: *The U.S. Food and Drug Administration recently conditionally approved PALSONIFY as the trade name for paltusotine, our once-daily, oral investigational candidate for acromegaly. PALSONIFY™ (paltusotine) Presentations Title: Paltusotine Results in Improved Symptom Stability in Biochemically Controlled Acromegaly Authors: David Clemmons, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-043 Title: Effects of Paltusotine Treatment on Patient-Reported Symptoms of Acromegaly in Phase 3 Randomized Placebo-Controlled Studies (PATHFNDR-2 and PATHFNDR-1) Authors: Avery A. Rizio, PhD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P34 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (Except Cushing) II – ENDOExpo Poster Area: SUN-052 Title: Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension Authors: Beverly M. K. Biller, MD et. al. Date/Time: July 13, 2:45-3:00 PM Location: Session OR12-07 – Neuroendocrinology and Pituitary: Management of Pituitary Disorders – Room 201 Title: Once-Daily Oral Paltusotine in the Treatment of Patients With Biochemically Uncontrolled Acromegaly: Interim Results of the PATHFNDR-2 Open-Label Extension Authors: Monica R. Gadelha, MD, PhD et. al. Date/Time: July 14, 12:00–1:30 PM Location: Session P77 – Neuroendocrinology and Pituitary: Acromegaly, Prolactinoma, Other Functioning Pituitary Tumors (except Cushing) III – ENDOExpo: Poster Area; MON-069 Atumelnant Presentations Title: Reductions in Adrenal Volume in Patients With Congenital Adrenal Hyperplasia Receiving Once-Daily Oral Atumelnant (CRN04894): Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Tania A.S.S. Bachega, MD, PhD et. al. Date/Time: July 12, 12:15-1:45 PM Location: Session P18 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH I – ENDOExpo Poster Area: SAT-452 Title: Once-Daily Oral Atumelnant (CRN04894) Induces Rapid, Substantial, and Sustained Reductions of Androstenedione and 17‑Hydroxyprogesterone in Adults With Classical Congenital Adrenal Hyperplasia: Interim Results From a 12-Week, Phase 2, Open-Label Study Authors: Umasuthan Srirangalingam, MD, PhD et. al. Date/Time: July 12, 2:30-2:45 PM Location: Session OR07-06 – Adrenal (Excluding Mineralocorticoids): All About Congenital Adrenal Hyperplasia and Adrenal Insufficiency – Room 204 Title: -Rapid and Sustained Reduction of 11-Oxygenated Androgens in Adults With Classic Congenital Adrenal Hyperplasia Following Once-Daily Oral Atumelnant (CRN04894): Results From a 12-Week, Phase 2, Open-Label Study Authors: Nicole Reisch, MD et. al. Date/Time: July 13, 12:00-1:30 PM Location: Session P55 – Adrenal (Excluding Mineralocorticoids): Adrenal Insufficiency and CAH II – ENDOExpo Poster Area: SUN-438 Early-Stage Pipeline Presentations Title: Discovery and Characterization of an Orally Bioavailable Nonpeptide Thyroid Stimulating Hormone Receptor (TSHR) Antagonist for the Treatment of Graves' Disease and Thyroid Eye Disease Authors: Eulalia A. Coutinho, PhD et. al. Date/Time: July 14, 12:00-1:30 PM Location: Session P92 – Thyroid Biology and Disease: Benign Thyroid Disorders (Auto-Immune) II – ENDOExpo Poster Area: MON-365 Crinetics Sponsored Science & Innovation Theaters Title: Optimizing Long-Term Control in Acromegaly: Key to Improved Patient Outcomes Presenters: Shlomo Melmed, MB ChB; Christian J. Strasburger, MD Date/Time: July 14, 9:30 AM-10:30 AM Location: Theater 1 Title: Navigating the Complexities & Challenges of Acromegaly Management Presenters: Lisa B. Nachtigall, MD; Laurence Katznelson, MD; Scott Struthers, PhD Date/Time: July 14, 12:30 PM -1:30 PM Location: Theater 1 About PALSONIFY™ (Paltusotine) Crinetics' lead development candidate, PALSONIFY, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once-daily oral option for the control of acromegaly and carcinoid syndrome. In Phase 3 studies, once-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome, leading to the initiation of a Phase 3 trial for control of carcinoid syndrome in patients with neuroendocrine tumors. About Atumelnant Atumelnant, Crinetics' second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with the Phase 3 CALM-CAH trial and a Phase 1/2b trial in ADCS currently enrolling patients. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; the plans and timelines for the commercial launch PALSONIFY if approved; the potential clinical benefits of our TSHR antagonist, CRN12755, in patients across multiple indications, and the anticipated timing of clinical trials, registration applications or the therapeutic potential for our development candidates. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential,' 'upcoming' or 'continue' or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; geopolitical events may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the success of Crinetics' clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics' drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company's periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading 'Risk Factors' in Crinetics' periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2024 and quarterly report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Media: Natalie Badillo Head of Corporate Communications [email protected] (858) 345-6075
UPI
25-06-2025
- Health
- UPI
Study finds autoimmune diseases increase risk of mood disorders
People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or bipolar disorder, a new large-scale study says. Photo by Adobe Stock/HealthDay News People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or bipolar disorder, a new large-scale study says. The risk of mood disorders is 87% to 97% higher in people suffering from rheumatoid arthritis, inflammatory bowel disease, lupus, multiple sclerosis, psoriasis and Graves' syndrome, researchers reported Tuesday in the BMJ Mental Health. This risk remains higher even after accounting for other factors like age, income and family history of psychiatric disorders, researchers found. "Together, these results support the hypothesis that exposure to chronic inflammation may be associated with a greater risk for affective disorders," concluded the research team led by Arish Mudra Rakshasa-Loots with the University of Edinburgh Center for Clinical Brain Sciences in Britain. For the study, researchers drew on data from 1.5 million people participating in a new large-scale British health study. Upon recruitment to the ongoing study, people provided a history of their physical and mental health. In all, more than 37,800 of the study participants reported living with an autoimmune condition. About 29% of people with an autoimmune illness said they'd been previously diagnosed with a mood disorder, compared with 18% of the general population, results show. This included more than 25% versus 15% diagnosed with depression, and 21% versus nearly 13% diagnosed with anxiety. Women with autoimmune diseases were particularly vulnerable to mood disorders, affecting 32% compared with 21% among men, results show. "Theories suggest that sex hormones, chromosomal factors, and differences in circulating antibodies may partly explain these sex differences," researchers wrote. Women with depression tend to have higher levels of inflammatory chemicals in their bloodstream, researchers noted. "It is therefore possible that women may experience the compounding challenges of increased occurrence of autoimmunity and stronger effects of immune responses on mental health, resulting in the substantially higher prevalence of affective disorders observed in this study," the team wrote. Given these results, it might be worth regularly checking people with an autoimmune disease for mood disorders, researchers concluded. "Regular screening for mental health conditions may be integrated into clinical care for people who are diagnosed with autoimmune diseases, and especially women with these diagnoses, to enable early detection of affective disorders and delivery of tailored mental health interventions," researchers wrote. Further studies should be done to determine other problems linked to autoimmune diseases -- like chronic pain, fatigue, sleep disruptions and social isolation - contribute to the risk for mood disorders, researchers added. More information The U.S. Pain Foundation has more on autoimmune diseases and mental health. Copyright © 2025 HealthDay. All rights reserved.
